You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Sunday, October 1, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

      Ask the Experts:

      Advances in Managing the Heavily Treatment-Experienced Patient With HIV

      Read Overview

      Supported by an independent educational grant from ViiV Healthcare                                                                                

      Overview

      Individuals with HIV who are heavily treatment-experienced with viremia and resistance -- whether they are older patients who sequenced through many non-suppressive regimens, or adolescents/young adults who have survived perinatal HIV acquisition with limited antiretroviral agents available to them and despite adherence issues -- have limited treatment options, even in the current era with 7 classes of active drugs. These patients require highly individualized care from or in consultation with a specialist with experience evaluating and managing this niche population to select a regimen with at least 2 active drugs from at least 2 classes. In this collection of activities, leading experts in HIV medicine explore these challenges and offer practical guidance on how to evaluate patients in order to tailor a fully active antiretroviral regimen.

      Ask the Experts

      • SURVEY
        Ask the Experts
        Submit your questions for the members of our Steering Committee
        Ask the Experts

      CME Activities

      Advances in Managing HTE HIV

      How Do You Optimize Care for Heavily Treatment-Experienced PWH?

      Resources

      Downloadable Slide Kit
      Clinical Reference
      Related Links

      Steering Committee

      David A. Wohl, MD
      David A. Wohl, MD

      Steering Committee Chair

      Professor of Medicine
      Division of Infectious Diseases
      Site Leader, HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill
      University of North Carolina at Chapel Hill
      Chapel Hill, North Carolina

      Bio Video
      ​​Richard A. Elion, MD
      Rick Elion, MD

      Steering Committee Member

      Clinical Professor of Medicine
      George Washington University Director of Research
      Washington Health Institute Washington, DC

      Bio Video
      Mehri S. McKellar, MD
      Mehri S. McKellar, MD

      Steering Committee Member

      Associate Professor of Medicine
      Duke University School of Medicine
      Durham, North Carolina

      Bio Video
      Paul E. Sax, MD
      Paul E. Sax, MD

      Steering Committee Member

      Professor of Medicine
      Harvard Medical School
      Clinical Director of the Division of Infectious Diseases
      Brigham and Women's Hospital
      Boston, Massachusetts

      Bio Video

      Disclosures

      Steering Committee

      David A. Wohl, MD

      Steering Committee Chair

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Gilead; Janssen; Merck; ViiV Healthcare

      Received grants for clinical research from: Gilead; Merck; ViiV Healthcare

      Rick Elion, MD

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Gilead; Viiv Healthcare

      Served as a speaker or a member of a speakers bureau for: Gilead; Viiv Healthcare

      Received grants for clinical research from: Gilead; Viiv Healthcare

      Other: Employed by commercial interest at Trio Health, which receives grants from Gilead, Janssen, Merck, and Viiv Healthcare

      ​​Charles Ryan, MD
      Mehri S. McKellar, MD

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Gilead; Theratechnologies; ViiV Healthcare

      ​​​​David S Hong, MD
      Paul E. Sax, MD

      Steering Committee Member

      Disclosure: Paul E. Sax, MD, has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Gilead; Janssen; Merck; ViiV Healthcare

      Received grants for clinical research from: Gilead; ViiV Healthcare

      Discussion

      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.